- Completion of new supply agreement with GlaxoSmithKline (NYSE: GSK) for the production of Coreg CR microparticles.
- Completion of a license and development agreement with Eagle Pharmaceuticals for a Medusa-enabled subcutaneous formulation of tigecycline, an antibiotic currently indicated for the treatment of a variety of serious infections via intravenous administration.
- Signing of two further new Medusa projects.
Flamel reported total revenues in the third quarter 2011 of $10.4 million, versus $8.0 million in the year-ago period. License and research revenues were $2.7 million versus $4.1 million in the third quarter of 2010. Product sales and services during the quarter were $5.2 million, and included the impact of the supply agreement with an effective date of January 1, 2011, versus $1.8 million in the third quarter 2010. Other revenues during the third quarter of 2011, composed primarily of royalties on the sale of Coreg CR, were $2.5 million versus $2.1 million in the year-ago period.Costs and expenses during the third quarter of 2011 were $(9.2) million versus $(11.2) million in the year-ago period. Costs of goods and services sold in the quarter were $(1.1) million versus $(1.5) million in the year-ago period. Research and development expenses were $(5.5) million versus $(6.7) million in the third quarter of 2010. SG&A declined during the third quarter of 2011 to $(2.6) million from $(2.9) million in the year-ago period. Net gain in the third quarter of 2011 was $1.7 million, compared to a net loss of $(3.3) million in the third quarter of 2010. Net gain per share (basic and diluted) for the third quarter of 2011 was $0.07 versus a net loss per share (basic) of $(0.14) in the third quarter, 2010. Cash and marketable securities at the end of the third quarter totaled $29.5 million versus $32.1 a year ago. For the first nine months of 2011, Flamel reported total revenues of $24.0 million versus $23.6 million in the first nine months of 2010. License and research revenues during the period were $8.4 million versus $10.9 million in the year-ago period. Product sales and services during the first nine months of 2011 were $9.2 million versus $6.0 million in the first nine months of 2010. Other revenues during the first nine months of 2011 were $6.4 million versus $6.8 million in the year-ago period.
During the first nine months of 2011, total costs and expenses declined to $(31.3) million, from $(35.5) million in the year-ago period. Costs of goods and services sold in the first nine months of 2011 totaled $(4.4) million versus $(5.0) million in the year-ago period. Research and development expenses during the first nine months of 2011 were $(19.2) million versus $(21.8) million during the year-ago period. SG&A for the first nine months of 2011 amounted to $(7.6) million versus $(8.7) million in the year-ago period.Net loss in the first nine months of 2011 was $(6.7) million, compared to a net loss of $(11.7) million in the first nine months of last year. Net loss per share (basic) for the first nine months of 2011 was $(0.27), compared to net loss per share (basic) in the year-ago period of $(0.48). A conference call to discuss earnings is scheduled for 8:30 AM EDT on November 3, 2011. The dial-in number (for investors in the U.S. and Canada) is (1) 877-397-0286; the conference ID number is 3684795. International investors are invited to dial (1) 719-325-4770. Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump ® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa ® technology is designed to deliver controlled-release formulations of proteins, peptides, as well as other large and small molecules. Schedule attached This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words “anticipate,” “assume,” “believe,” “expect,” “estimate,” “plan,” will,” and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2010. All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.
|Financial Statements (Unaudited)|
|CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)|
|(Amounts in thousands of dollars except share data)|
|Three months ended September 30,||Nine months ended September 30,|
|License and research revenue||$4,119||$2,700||$10,865||$8,396|
|Product sales and services||1,805||5,239||5,970||9,153|
|Costs and expenses:|
|Cost of goods and services sold||(1,535||)||(1,129||)||(5,045||)||(4,434||)|
|Research and development||(6,702||)||(5,475||)||(21,824||)||(19,179||)|
|Selling, general and administrative||(2,931||)||(2,590||)||(8,659||)||(7,644||)|
|Income (loss) from operations||(3,127||)||1,240||(11,885||)||(7,306||)|
|Interest income net||109||147||326||472|
|Foreign exchange gain (loss)||(302||)||375||(87||)||155|
|Other income (loss)||5||(12||)||93||129|
|Income (loss) before income taxes||(3,315||)||1,750||(11,553||)||(6,550||)|
|Income tax benefit (expense)||(24||)||(47||)||(100||)||(133||)|
|Net income (loss)||($3,339||)||$1,703||($11,653||)||($6,683||)|
|Earnings (loss) per share|
|Basic earnings (loss) per ordinary share||($0.14||)||$0.07||($0.48||)||($0.27||)|
|Diluted earnings (loss) per share||($0.14||)||$0.07||($0.48||)||($0.27||)|
|Weighted average number of shares outstanding (in thousands):|